Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Zai Lab LimitedNASDAQ: ZLAB

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -47.8%

Net margin was -47.8% in Q2 FY2026, down 10.8 pp from a year earlier. On a trailing-twelve-month basis it was -41.9%, up 7.8 pp year over year. Over 3 fiscal years it widened by 168.0 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 7 analysts of -50.3% for the fiscal year ending Dec 2026, down from -38.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-47.8%+3.4 pp QoQ
Last fiscal yearDec 2025
-38.1%+26.3 pp YoY
LTMJun 2026
-41.9%+7.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.8 pp-30.6 pp-19.9 pp
1 year+26.3 pp-12.1 pp-38.4 pp
3 years+168.0 pp+17.5 pp-150.5 pp
5 years+58.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-38.1%
Year-over-year change
+26.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ZLAB compares with its peers on the latest reported figures

  • ZLAB's LTM Jun 2026 net margin of -41.9% is the 2nd highest of the 4 companies compared; the peer median is -216.5%.
  • Its year-over-year change of +7.8 pp is the 2nd highest of 3, against a peer median of -45.4 pp.
  • Over three fiscal years its change of +168.0 pp compares with a peer median of +186.2 pp.
ZLAB Competitors Peer median
Net Margin for ZLAB and competitors
Company Period LTM level YoY 3-year change
HCMHUTCHMED (China) LimitedLTM Jun 202577.5% +84.4 pp+167.9 pp
ZLABZai Lab LimitedLTM Jun 2026-41.9% +7.8 pp+168.0 pp
AAPGAscentage Pharma Group InternationalFY2025-216.5% -175.1 pp+204.6 pp
ANLAdlai Nortye Ltd.LTM Jun 2024-833.1% ——
Peer median (excluding ZLAB) -216.5%-45.4 pp+186.2 pp

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.